Premium
Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study
Author(s) -
Arana Alejandro,
Margulis Andrea V.,
McQuay Lisa J.,
Ziemiecki Ryan,
Bartsch Jennifer L.,
Rothman Kenneth J.,
Franks Billy,
D'Silva Milbhor,
Appenteng Kwame,
VarasLorenzo Cristina,
PerezGutthann Susana
Publication year - 2018
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2121
Subject(s) - tolterodine , solifenacin , overactive bladder , medicine , oxybutynin , mace , cohort , cohort study , myocardial infarction , alternative medicine , pathology , conventional pci
Background Blocking muscarinic receptors could have an effect on cardiac function, especially among elderly patients with overactive bladder ( OAB ). Study Objective To investigate the risk of cardiovascular (CV) events in users of antimuscarinic drugs to treat OAB . Design, Setting, and Participants Cohort study of new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium, 18 years or older, in the United Kingdom's Clinical Practice Research Datalink ( CPRD ), 2004–2012. Outcome Measurements and Main Results Using tolterodine as the reference, we estimated propensity‐score–stratified incidence rate ratios ( IRR s) for acute myocardial infarction, stroke, CV mortality, major adverse cardiac events ( MACE , a combined end point of the previous three), and all‐cause death for individual antimuscarinic drugs. The study cohort included 119,912 new users of OAB drugs. The mean age at cohort entry was 62 years, 70% were female, and the mean follow‐up was 3.3 years. The adjusted IRR for MACE and current use of oxybutynin compared with current use of tolterodine was 1.14 (95% confidence interval [CI] 1.01–1.30). In contrast, the IRR was 0.65 (CI 0.56–0.76) for current use of solifenacin compared with tolterodine. In this study, performed with health care data, the distribution of risk factors was relatively similar across users of different OAB drugs and, although our analyses controlled for a range of measured potential confounders, residual confounding cannot be ruled out. Conclusions In an observational comparative study of users of medications to treat OAB conducted in routine clinical practice, the risk for CV side effects was increased in users of oxybutynin and decreased in users of solifenacin compared with users of tolterodine.